Market Overview:
The global male hypogonadism market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of testosterone deficiency and other associated disorders, rising awareness about the benefits of testosterone replacement therapy (TRT), and growing demand for gonadotropin-releasing hormones therapy (GnRH therapy). However, certain factors such as the high cost of treatment and side effects associated with TRT are likely to restrain the growth of this market in some regions. The global male hypogonadism market can be segmented on the basis of type into testosterone replacement therapy (TRT) and GnRH therapy. TRT is currently more popular than GnRH therapy owing to its lower cost and better efficacy profile. However, GnRH therapies are gaining popularity due their ability to achieve long-term remission in patients with prostate cancer. On the basis of application, the global male hypogonadism market can be divided into Kallmann syndrome, Klinefelters syndrome, pituitary disorders, and others (including cryptorchidism and varicocele). The majority share in this market is held by pituitary disorders owing to their high prevalence rate worldwide.
Product Definition:
Male hypogonadism is a condition in which the body doesn't produce enough testosterone. The lack of testosterone can cause a number of problems, including infertility, low sex drive, and osteoporosis. Treatment typically involves taking replacement therapy with testosterone.
Testosterone Replacement Therapy:
Testosterone replacement therapy is the treatment of hypogonadism which occurs as a result of low or absence of testosterone production in the body. Testosterone replacement therapy can be administered through various routes depending upon patient requirements and physician’s choice. The most commonly used route is oral administration followed by transdermal patch, gels and injections.
Gonadotropin-Releasing Hormones Therapy:
Gonadotropin-releasing hormones (GnRH) therapy is used in male hypogonadism to stimulate the production of testosterone by the testes. Testosterone deficiency is a common problem in men, which often goes undiagnosed due to lack of awareness among patients.
Application Insights:
Kallmann syndrome held the largest revenue share of over 27.0% in 2017. The disease is named after its discoverer, Hans Kallmann, who first reported it in 1969. According to the National Center for Biotechnology Information (NCBI) there are approximately 60 patients worldwide with this condition and fewer than 10 cases have been reported from India till date.
The other application segment consists of testosterone deficiency due to primary testicular failure or cancer treatment-induced hypogonadism which occurs relatively more often compared to Kallmann syndrome across the globe owing to increased awareness about these disorders and availability of advanced diagnostic tools for early diagnosis coupled with effective treatment options that help boost market growth during this study period.
Regional Analysis:
North America dominated the global male hypogonadism market in 2017. The presence of well-established healthcare facilities and a high prevalence of Kallmann syndrome, gonadal mosaicism, and other pituitary disorders are some factors responsible for its large share. In addition, increasing awareness about various treatment options is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India.
Growth Factors:
- Increasing awareness about the condition and its treatment options among people, especially men
- Growing prevalence of lifestyle diseases such as obesity and diabetes, which are known to cause Male Hypogonadism
- Rising demand for testosterone replacement therapy (TRT) as a treatment for Male Hypogonadism
- increasing research on Male Hypogonadism and its potential treatments
- growing number of men who are willing to seek medical help for their symptoms
Scope Of The Report
Report Attributes
Report Details
Report Title
Male Hypogonadism Market Research Report
By Type
Testosterone Replacement Therapy, Gonadotropin-Releasing Hormones Therapy
By Application
Kallmann Syndrome, Klinefelters Syndrome, Pituitary Disorders, Others
By Companies
Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd., Finox Biotech, Teva Pharmaceutical Industries Ltd., Bayer AG, IBSA Institut Biochimque
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
128
Number of Tables & Figures
90
Customization Available
Yes, the report can be customized as per your need.
Global Male Hypogonadism Market Report Segments:
The global Male Hypogonadism market is segmented on the basis of:
Types
Testosterone Replacement Therapy, Gonadotropin-Releasing Hormones Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Kallmann Syndrome, Klinefelters Syndrome, Pituitary Disorders, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astrazeneca Plc.
- Merck & Co. Inc.
- Laboratories Genevrier
- Allergan Plc.
- Endo International Plc.
- Ferring
- AbbVie Inc.
- Eli Lilly and Company Ltd.
- Finox Biotech
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- IBSA Institut Biochimque
Highlights of The Male Hypogonadism Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Testosterone Replacement Therapy
- Gonadotropin-Releasing Hormones Therapy
- By Application:
- Kallmann Syndrome
- Klinefelters Syndrome
- Pituitary Disorders
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Male Hypogonadism Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Male hypogonadism is a condition in which the body does not produce enough testosterone. This can be caused by many things, including age, genetics, and health problems. Male hypogonadism can lead to problems with sexual function, mood swings, fatigue, and decreased muscle mass.
Some of the key players operating in the male hypogonadism market are Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd., Finox Biotech, Teva Pharmaceutical Industries Ltd., Bayer AG, IBSA Institut Biochimque.
The male hypogonadism market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Male Hypogonadism Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Male Hypogonadism Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Male Hypogonadism Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Male Hypogonadism Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Male Hypogonadism Market Size & Forecast, 2018-2028
4.5.1 Male Hypogonadism Market Size and Y-o-Y Growth
4.5.2 Male Hypogonadism Market Absolute $ Opportunity
Chapter 5 Global Male Hypogonadism Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Male Hypogonadism Market Size Forecast by Type
5.2.1 Testosterone Replacement Therapy
5.2.2 Gonadotropin-Releasing Hormones Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Male Hypogonadism Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Male Hypogonadism Market Size Forecast by Applications
6.2.1 Kallmann Syndrome
6.2.2 Klinefelters Syndrome
6.2.3 Pituitary Disorders
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Male Hypogonadism Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Male Hypogonadism Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Male Hypogonadism Analysis and Forecast
9.1 Introduction
9.2 North America Male Hypogonadism Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Male Hypogonadism Market Size Forecast by Type
9.6.1 Testosterone Replacement Therapy
9.6.2 Gonadotropin-Releasing Hormones Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Male Hypogonadism Market Size Forecast by Applications
9.10.1 Kallmann Syndrome
9.10.2 Klinefelters Syndrome
9.10.3 Pituitary Disorders
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Male Hypogonadism Analysis and Forecast
10.1 Introduction
10.2 Europe Male Hypogonadism Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Male Hypogonadism Market Size Forecast by Type
10.6.1 Testosterone Replacement Therapy
10.6.2 Gonadotropin-Releasing Hormones Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Male Hypogonadism Market Size Forecast by Applications
10.10.1 Kallmann Syndrome
10.10.2 Klinefelters Syndrome
10.10.3 Pituitary Disorders
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Male Hypogonadism Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Male Hypogonadism Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Male Hypogonadism Market Size Forecast by Type
11.6.1 Testosterone Replacement Therapy
11.6.2 Gonadotropin-Releasing Hormones Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Male Hypogonadism Market Size Forecast by Applications
11.10.1 Kallmann Syndrome
11.10.2 Klinefelters Syndrome
11.10.3 Pituitary Disorders
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Male Hypogonadism Analysis and Forecast
12.1 Introduction
12.2 Latin America Male Hypogonadism Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Male Hypogonadism Market Size Forecast by Type
12.6.1 Testosterone Replacement Therapy
12.6.2 Gonadotropin-Releasing Hormones Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Male Hypogonadism Market Size Forecast by Applications
12.10.1 Kallmann Syndrome
12.10.2 Klinefelters Syndrome
12.10.3 Pituitary Disorders
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Male Hypogonadism Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Male Hypogonadism Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Male Hypogonadism Market Size Forecast by Type
13.6.1 Testosterone Replacement Therapy
13.6.2 Gonadotropin-Releasing Hormones Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Male Hypogonadism Market Size Forecast by Applications
13.10.1 Kallmann Syndrome
13.10.2 Klinefelters Syndrome
13.10.3 Pituitary Disorders
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Male Hypogonadism Market: Competitive Dashboard
14.2 Global Male Hypogonadism Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astrazeneca Plc.
14.3.2 Merck & Co. Inc.
14.3.3 Laboratories Genevrier
14.3.4 Allergan Plc.
14.3.5 Endo International Plc.
14.3.6 Ferring
14.3.7 AbbVie Inc.
14.3.8 Eli Lilly and Company Ltd.
14.3.9 Finox Biotech
14.3.10 Teva Pharmaceutical Industries Ltd.
14.3.11 Bayer AG
14.3.12 IBSA Institut Biochimque
